The Phase I and II results of Oxford-AstraZeneca COVID-19 vaccine trials are encouraging. Data from the vaccine, called AZD1222, suggest it is safe, well-tolerated and immunogenic, medical journal ‘The Lancet’ said
Follow us:
Website:
Facebook:
Twitter:
Instagram:
#moneycontrol
